Abstract
Neoadjuvant treatment plays an important role in the downstaging of rectal cancer. Some patients who are treated in this way will develop a complete clinical response (1). The adoption of a “watch and wait” policy for patients who have undergone complete clinical response is now accepted in many centres (2,3). An intensive follow-up protocol, including clinical, endoscopic and magnetic resonance imaging (MRI) assessment every four months for the first 2 years is recommended (3). Studies have shown that despite some excellent responses to the initial treatment, up to 30% of patients will develop a regrowth requiring surgical resection (1–3). This article is protected by copyright. All rights reserved.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
